Vergelijking
DSIP vs. Glepaglutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
62568-57-4
geen gegevens
Molecuulmassa
848.81 g/mol
geen gegevens
Halfwaardetijd
0.1 h
geen gegevens
Sequentie
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glugeen gegevens
Werkingsmechanisme
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
1
waarvan bij mensen
1
1
Geregistreerde effecten
3
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between DSIP and Glepaglutide?
- DSIP is classified as "Onderzoek (overig)", while Glepaglutide is classified as "Onderzoek (overig)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Glepaglutide?
- The highest available evidence level is "Humane studie" for DSIP and "Humane RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Glepaglutide in Germany and the United States?
- Duitsland: DSIP — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. Verenigde Staten: DSIP — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.